← FDA DRUG APPROVALS

FDA ANDA · ANDA207384

DEFEROXAMINE MESYLATE

Sponsor: GLAND

APPLICATION
ANDA207384
TYPE
ANDA
ORIGINAL APPROVAL
2017-09-29
LATEST ACTION
2024-02-05
ROUTE
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DEFEROXAMINE MESYLATEPrescription
DEFEROXAMINE MESYLATE 500MG/VIAL · INJECTABLE · INJECTION
DEFEROXAMINE MESYLATEPrescription
DEFEROXAMINE MESYLATE 2GM/VIAL · INJECTABLE · INJECTION

Approval history

2024-02-05Labeling · Supplement 2 · standardAP
2017-09-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →